Zoetis: An Undervalued Compounder Hiding In Plain Sight

Summary Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment. I expect margins and growth to recover as competitive pressures ease, with management signaling confidence through increased buybacks and disciplined capital allocation. Julia Suhareva/iStock via Getty Images Zoetis Inc. ( ZTS ) is a leading animal health company. The company researches, develops, and manufactures companion animal and livestock vaccines, medicines, diagnostics, and technologies to advance animal care worldwide. Since the COVID-19 recovery boom, the company’s stock has been declining steadily. Zoetis This article was written by Natural Born Value Seeker 122 Followers Follow I am a highly determined and competitive individual on a lifelong quest to compound happiness, wisdom, and wealth.I am passionate about financial markets and behavioral economics. I thoroughly enjoy researching investment ideas of my role models, such as Warren Buffett, the late Charlie Munger, Mohnish Pabrai, Li Lu, Bill Nygren, and Seth Klarman, among others. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ZTS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.